Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer.

CA Cancer J Clin · 2026 · PMC13179593 · PMID 42141924

Europe PMC DOI

hedged sentence

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

borderline significantp = .061so close (0.05 < p ≤ 0.1)

Only the number of lymph nodes examined resulted in a borderline significant interaction ( p = .061), which suggests that the IM‐MS‐RT benefit may be more favorable in the subgroup of patients who have <10 axillary lymph nodes examined compared with those who have ≥10 lymph nodes examined (Figure 2 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.